Naxitamab is a monoclonal antibody that targets the GD2 glycolipid present on the surface of neuroblastoma tumor cells and some normal cells. Naxitamab will bind to GD2 and cause cells to break down and die.

Neuroblastoma is an extremely dangerous disease and is common in children. The disease causes many complications such as metastasis, compression of the spine and paraneoplastic syndrome. When conducting treatment, doctors will depend on the age at the time of diagnosis, the stage of the disease, the location of the tumor, the metastasis and the level of tumor activity, to choose the treatment method. Fit.